Abstract:Objective To explore the clinical efficacy and safety of MORA bioresonance therapy combined with budesonide/formoterol in the treatment of allergic bronchial asthma. Methods Sixty patients with bronchial asthma meeting the inclusion criteria from June 2016 to December 2017 were randomly divided into control group and experimental group (n=30, each). The budesonide/formoterol plus conventional treatment was given in control group, and MORA bioresonance therapy was added in experimental group based on the treatment regimen of control group. At 3 and 6 months after treatment, daytime/night symptom score, asthma quality of life questionnaire, pulmonary function index, clinical efficacy and adverse reactions were observed and compared between two groups. Results Before treatment, there were no significant differences in daytime/night symptom score, asthma quality of life questionnaire and pulmonary function index (FEV₁, FEV₁%, PEF) between two groups (all P>0.05). Compared with before treatment, the above-mentioned indexes were significantly improved after treatment in both two groups (all P<0.05). After 3-and 6-month of treatment, all observation indexes in experimental group significantly improved compared with those in control group (P<0.05). The curative effect in experimental group was statistically better than that in control group (93. 33% vs 66. 67%, P<0.05). In control group, there were 3 cases with tremor, and 4 cases with gastrointestinal symptoms. In experimental group, tremor occurred in 2 cases, gastrointestinal symptoms occurred in 4 cases. There was no significant difference in the incidence of adverse reactions between experimental group and control group (23. 33% vs 20.00%, P>0.05). Conclusion MORA bioresonance therapy combined with budesonide/formoterol has obvious effect in the treatment of allergic bronchial asthma and can improve patient′s lung function and clinical symptoms more effectively without increasing the incidence of adverse reactions.